Allozyne goes public via merger with Poniard

San Francisco's Poniard Pharmaceuticals and Seattle-based Allozyne are both getting what they want out of a merger deal announced yesterday. Allozyne, which is developing protein therapeutics for multiple sclerosis, is purchasing the NASDAQ-listed Poniard, with Allozyne shareholders gaining 65 percent of the combined company's stock. That gives the Seattle developer access to the public markets without the hassle of a tricky IPO. Allozyne CEO Meenu Chhabra will head up the combined company.

Poniard has been cutting staff and evaluating its options since 2009, when its cancer drug picoplatin flunked a Phase III trial. The developer has been operating on autopilot ever since. The combined company will focus its resources on advancing pipeline and platform technology. The companies will seek a partner to continue development of picoplatin.

"We believe that Allozyne's proprietary platform may enable us to enhance virtually any biologic therapeutic, including therapeutic proteins and antibodies," noted Chhabra in a release. "Our lead product, AZ01, a clinical-stage, PEGylated interferon β for multiple sclerosis, could replace existing weekly or twice-weekly interferon treatment with monthly dosing and has the potential to address a significant unmet need in this multi-billion dollar market. By merging with Poniard, we believe we can access the public capital markets to accelerate our strategic plan." The company's priority will be to advance AZ01 into a Phase II study.

- check out Allozyne's release
- read more from Xconomy

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.